Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J D Becherer

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
British Journal of Pharmacology|July 1, 2008
Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig modelX Yao, D L Anderson, S A Ross, et al.
Journal of Neuroimmunology|February 1, 1997
Structural features and biochemical properties of TNF-alpha converting enzyme (TACE)M L Moss, S L Jin, J D Becherer, et al.
Journal of Medicinal Chemistry|November 16, 2001
Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)M H Rabinowitz, R C Andrews, J D Becherer, et al.
The Journal of Biological Chemistry|October 16, 1999
Specific sequence elements are required for the expression of functional tumor necrosis factor-alpha-converting enzyme (TACE)M E Milla, M A Leesnitzer, M L Moss, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 16, 2001
Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinasesJ G Conway, R C Andrews, B Beaudet, et al.
Nature|February 20, 1997
Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alphaM L Moss, S L Jin, M E Milla, et al.
Bioorganic & Medicinal Chemistry Letters|August 22, 2001
N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitutionD L Musso, M W Andersen, R C Andrews, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
British Journal of Pharmacology|July 1, 2008
Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig modelX Yao, D L Anderson, S A Ross, et al.
Journal of Neuroimmunology|February 1, 1997
Structural features and biochemical properties of TNF-alpha converting enzyme (TACE)M L Moss, S L Jin, J D Becherer, et al.
Journal of Medicinal Chemistry|November 16, 2001
Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)M H Rabinowitz, R C Andrews, J D Becherer, et al.
The Journal of Biological Chemistry|October 16, 1999
Specific sequence elements are required for the expression of functional tumor necrosis factor-alpha-converting enzyme (TACE)M E Milla, M A Leesnitzer, M L Moss, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 16, 2001
Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinasesJ G Conway, R C Andrews, B Beaudet, et al.
Nature|February 20, 1997
Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alphaM L Moss, S L Jin, M E Milla, et al.
Bioorganic & Medicinal Chemistry Letters|August 22, 2001
N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitutionD L Musso, M W Andersen, R C Andrews, et al.
Pageof 3